Genomic sequence of chorioallantois vaccinia virus Ankara, the ancestor of modified vaccinia virus Ankara

Meisinger-Henschel C, Schmidt M, Lukassen S, Linke B, Krause L, Konietzny S, Goesmann A, Howley P, Chaplin P, Suter M, Hausmann J (2007)
JOURNAL OF GENERAL VIROLOGY 88(12): 3249-3259.

Zeitschriftenaufsatz | Veröffentlicht | Englisch
 
Download
Es wurden keine Dateien hochgeladen. Nur Publikationsnachweis!
DOI
Autor*in
Meisinger-Henschel, Christine; Schmidt, Michaela; Lukassen, Susanne; Linke, BurkhardUniBi; Krause, Lutz; Konietzny, Sebastian; Goesmann, AlexanderUniBi ; Howley, Paul; Chaplin, Paul; Suter, Mark; Hausmann, Juergen
Einrichtung
Technische Fakultät > AG Genominformatik
Centrum für Biotechnologie > Institut für Bioinformatik
Centrum für Biotechnologie > Arbeitsgruppe A. Goesmann
Centrum für Biotechnologie > Technologieplattformen > Bioinformatics Resource Facility
Technische Fakultät > Computational Genomics
Erscheinungsjahr
2007
Zeitschriftentitel
JOURNAL OF GENERAL VIROLOGY
Band
88
Ausgabe
12
Seite(n)
3249-3259
ISSN
0022-1317
eISSN
1465-2099
Page URI
https://pub.uni-bielefeld.de/record/1631047

Zitieren

Meisinger-Henschel C, Schmidt M, Lukassen S, et al. Genomic sequence of chorioallantois vaccinia virus Ankara, the ancestor of modified vaccinia virus Ankara. JOURNAL OF GENERAL VIROLOGY. 2007;88(12):3249-3259.
Meisinger-Henschel, C., Schmidt, M., Lukassen, S., Linke, B., Krause, L., Konietzny, S., Goesmann, A., et al. (2007). Genomic sequence of chorioallantois vaccinia virus Ankara, the ancestor of modified vaccinia virus Ankara. JOURNAL OF GENERAL VIROLOGY, 88(12), 3249-3259. https://doi.org/10.1099/vir.0.83156-0
Meisinger-Henschel, Christine, Schmidt, Michaela, Lukassen, Susanne, Linke, Burkhard, Krause, Lutz, Konietzny, Sebastian, Goesmann, Alexander, et al. 2007. “Genomic sequence of chorioallantois vaccinia virus Ankara, the ancestor of modified vaccinia virus Ankara”. JOURNAL OF GENERAL VIROLOGY 88 (12): 3249-3259.
Meisinger-Henschel, C., Schmidt, M., Lukassen, S., Linke, B., Krause, L., Konietzny, S., Goesmann, A., Howley, P., Chaplin, P., Suter, M., et al. (2007). Genomic sequence of chorioallantois vaccinia virus Ankara, the ancestor of modified vaccinia virus Ankara. JOURNAL OF GENERAL VIROLOGY 88, 3249-3259.
Meisinger-Henschel, C., et al., 2007. Genomic sequence of chorioallantois vaccinia virus Ankara, the ancestor of modified vaccinia virus Ankara. JOURNAL OF GENERAL VIROLOGY, 88(12), p 3249-3259.
C. Meisinger-Henschel, et al., “Genomic sequence of chorioallantois vaccinia virus Ankara, the ancestor of modified vaccinia virus Ankara”, JOURNAL OF GENERAL VIROLOGY, vol. 88, 2007, pp. 3249-3259.
Meisinger-Henschel, C., Schmidt, M., Lukassen, S., Linke, B., Krause, L., Konietzny, S., Goesmann, A., Howley, P., Chaplin, P., Suter, M., Hausmann, J.: Genomic sequence of chorioallantois vaccinia virus Ankara, the ancestor of modified vaccinia virus Ankara. JOURNAL OF GENERAL VIROLOGY. 88, 3249-3259 (2007).
Meisinger-Henschel, Christine, Schmidt, Michaela, Lukassen, Susanne, Linke, Burkhard, Krause, Lutz, Konietzny, Sebastian, Goesmann, Alexander, Howley, Paul, Chaplin, Paul, Suter, Mark, and Hausmann, Juergen. “Genomic sequence of chorioallantois vaccinia virus Ankara, the ancestor of modified vaccinia virus Ankara”. JOURNAL OF GENERAL VIROLOGY 88.12 (2007): 3249-3259.

42 Zitationen in Europe PMC

Daten bereitgestellt von Europe PubMed Central.

SPI-1 is a missing host-range factor required for replication of the attenuated modified vaccinia Ankara (MVA) vaccine vector in human cells.
Liu R, Mendez-Rios JD, Peng C, Xiao W, Weisberg AS, Wyatt LS, Moss B., PLoS Pathog 15(5), 2019
PMID: 31145755
Swinepox virus vector-based vaccines: attenuation and biosafety assessments following subcutaneous prick inoculation.
Yuan X, Lin H, Li B, He K, Fan H., Vet Res 49(1), 2018
PMID: 29415767
Virulent Poxviruses Inhibit DNA Sensing by Preventing STING Activation.
Georgana I, Sumner RP, Towers GJ, Maluquer de Motes C., J Virol 92(10), 2018
PMID: 29491158
Recombinant Modified Vaccinia Virus Ankara Generating Ebola Virus-Like Particles.
Schweneker M, Laimbacher AS, Zimmer G, Wagner S, Schraner EM, Wolferstätter M, Klingenberg M, Dirmeier U, Steigerwald R, Lauterbach H, Hochrein H, Chaplin P, Suter M, Hausmann J., J Virol 91(11), 2017
PMID: 28331098
Tissue plasminogen activator (tPA) signal sequence enhances immunogenicity of MVA-based vaccine against tuberculosis.
Kou Y, Xu Y, Zhao Z, Liu J, Wu Y, You Q, Wang L, Gao F, Cai L, Jiang C., Immunol Lett 190(), 2017
PMID: 28728855
Deletion of A44L, A46R and C12L Vaccinia Virus Genes from the MVA Genome Improved the Vector Immunogenicity by Modifying the Innate Immune Response Generating Enhanced and Optimized Specific T-Cell Responses.
Holgado MP, Falivene J, Maeto C, Amigo M, Pascutti MF, Vecchione MB, Bruttomesso A, Calamante G, Del Médico-Zajac MP, Gherardi MM., Viruses 8(5), 2016
PMID: 27223301
Modified Vaccinia Ankara Virus Vaccination Provides Long-Term Protection against Nasal Rabbitpox Virus Challenge.
Jones DI, McGee CE, Sample CJ, Sempowski GD, Pickup DJ, Staats HF., Clin Vaccine Immunol 23(7), 2016
PMID: 27146001
Truncation of gene F5L partially masks rescue of vaccinia virus strain MVA growth on mammalian cells by restricting plaque size.
Dobson BM, Tscharke DC., J Gen Virol 95(pt 2), 2014
PMID: 24145605
Deletion of the vaccinia virus N2L gene encoding an inhibitor of IRF3 improves the immunogenicity of modified vaccinia virus Ankara expressing HIV-1 antigens.
García-Arriaza J, Gómez CE, Sorzano CÓ, Esteban M., J Virol 88(6), 2014
PMID: 24390336
A novel vaccine against Crimean-Congo Haemorrhagic Fever protects 100% of animals against lethal challenge in a mouse model.
Buttigieg KR, Dowall SD, Findlay-Wilson S, Miloszewska A, Rayner E, Hewson R, Carroll MW., PLoS One 9(3), 2014
PMID: 24621656
Matrix and backstage: cellular substrates for viral vaccines.
Jordan I, Sandig V., Viruses 6(4), 2014
PMID: 24732259
Modified vaccinia virus Ankara triggers type I IFN production in murine conventional dendritic cells via a cGAS/STING-mediated cytosolic DNA-sensing pathway.
Dai P, Wang W, Cao H, Avogadri F, Dai L, Drexler I, Joyce JA, Li XD, Chen Z, Merghoub T, Shuman S, Deng L., PLoS Pathog 10(4), 2014
PMID: 24743339
A single vertebrate DNA virus protein disarms invertebrate immunity to RNA virus infection.
Gammon DB, Duraffour S, Rozelle DK, Hehnly H, Sharma R, Sparks ME, West CC, Chen Y, Moresco JJ, Andrei G, Connor JH, Conte D, Gundersen-Rindal DE, Marshall WL, Yates JR, Silverman N, Mello CC., Elife 3(), 2014
PMID: 24966209
Recombinant modified vaccinia virus Ankara generating excess early double-stranded RNA transiently activates protein kinase R and triggers enhanced innate immune responses.
Wolferstätter M, Schweneker M, Späth M, Lukassen S, Klingenberg M, Brinkmann K, Wielert U, Lauterbach H, Hochrein H, Chaplin P, Suter M, Hausmann J., J Virol 88(24), 2014
PMID: 25297997
Genetic screen of a library of chimeric poxviruses identifies an ankyrin repeat protein involved in resistance to the avian type I interferon response.
Buttigieg K, Laidlaw SM, Ross C, Davies M, Goodbourn S, Skinner MA., J Virol 87(9), 2013
PMID: 23427151
Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial.
Walsh SR, Wilck MB, Dominguez DJ, Zablowsky E, Bajimaya S, Gagne LS, Verrill KA, Kleinjan JA, Patel A, Zhang Y, Hill H, Acharyya A, Fisher DC, Antin JH, Seaman MS, Dolin R, Baden LR., J Infect Dis 207(12), 2013
PMID: 23482644
Clinical development of Modified Vaccinia virus Ankara vaccines.
Gilbert SC., Vaccine 31(39), 2013
PMID: 23523410
Attenuation and immunogenicity of host-range extended modified vaccinia virus Ankara recombinants.
Melamed S, Wyatt LS, Kastenmayer RJ, Moss B., Vaccine 31(41), 2013
PMID: 23928462
A novel naturally occurring tandem promoter in modified vaccinia virus ankara drives very early gene expression and potent immune responses.
Wennier ST, Brinkmann K, Steinhäußer C, Mayländer N, Mnich C, Wielert U, Dirmeier U, Hausmann J, Chaplin P, Steigerwald R., PLoS One 8(8), 2013
PMID: 23951355
Elements in the Development of a Production Process for Modified Vaccinia Virus Ankara.
Jordan I, Lohr V, Genzel Y, Reichl U, Sandig V., Microorganisms 1(1), 2013
PMID: 27694766
Environmental risk assessment of clinical trials involving modified vaccinia virus Ankara (MVA)-based vectors.
Goossens M, Pauwels K, Willemarck N, Breyer D., Curr Gene Ther 13(6), 2013
PMID: 24397528
Measurement of antibody responses to Modified Vaccinia virus Ankara (MVA) and Dryvax(®) using proteome microarrays and development of recombinant protein ELISAs.
Hermanson G, Chun S, Felgner J, Tan X, Pablo J, Nakajima-Sasaki R, Molina DM, Felgner PL, Liang X, Davies DH., Vaccine 30(3), 2012
PMID: 22100890
The vaccinia virus O1 protein is required for sustained activation of extracellular signal-regulated kinase 1/2 and promotes viral virulence.
Schweneker M, Lukassen S, Späth M, Wolferstätter M, Babel E, Brinkmann K, Wielert U, Chaplin P, Suter M, Hausmann J., J Virol 86(4), 2012
PMID: 22171261
Attenuation of vaccinia Tian Tan strain by removal of viral TC7L-TK2L and TA35R genes.
Kan S, Wang Y, Sun L, Jia P, Qi Y, Su J, Liu L, Yang G, Liu L, Wang Z, Wang J, Liu G, Jin N, Li X, Ding Z., PLoS One 7(2), 2012
PMID: 22363781
A cross-species view on viruses.
Sawyer SL, Elde NC., Curr Opin Virol 2(5), 2012
PMID: 22835485
Orthopoxvirus genes that mediate disease virulence and host tropism.
Shchelkunov SN., Adv Virol 2012(), 2012
PMID: 22899927
Poxviruses deploy genomic accordions to adapt rapidly against host antiviral defenses.
Elde NC, Child SJ, Eickbush MT, Kitzman JO, Rogers KS, Shendure J, Geballe AP, Malik HS., Cell 150(4), 2012
PMID: 22901812
Characterization of indels in poxvirus genomes.
Coulson D, Upton C., Virus Genes 42(2), 2011
PMID: 21153876
Deletion of the A35 gene from Modified Vaccinia Virus Ankara increases immunogenicity and isotype switching.
Rehm KE, Roper RL., Vaccine 29(17), 2011
PMID: 21352940
Deletion of major nonessential genomic regions in the vaccinia virus Lister strain enhances attenuation without altering vaccine efficacy in mice.
Dimier J, Ferrier-Rembert A, Pradeau-Aubreton K, Hebben M, Spehner D, Favier AL, Gratier D, Garin D, Crance JM, Drillien R., J Virol 85(10), 2011
PMID: 21367889
The strategic use of novel smallpox vaccines in the post-eradication world.
Golden JW, Hooper JW., Expert Rev Vaccines 10(7), 2011
PMID: 21806397
Vaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumors.
Walsh SR, Dolin R., Expert Rev Vaccines 10(8), 2011
PMID: 21854314
Innate immune recognition of poxviral vaccine vectors.
Lousberg EL, Diener KR, Brown MP, Hayball JD., Expert Rev Vaccines 10(10), 2011
PMID: 21988308
A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE.
von Krempelhuber A, Vollmar J, Pokorny R, Rapp P, Wulff N, Petzold B, Handley A, Mateo L, Siersbol H, Kollaritsch H, Chaplin P., Vaccine 28(5), 2010
PMID: 19944151
Mutations in modified virus Ankara protein 183 render it a non-functional counterpart of B14, an inhibitor of nuclear factor kappaB activation.
McCoy LE, Fahy AS, Chen RA, Smith GL., J Gen Virol 91(pt 9), 2010
PMID: 20444990
Introduction of the six major genomic deletions of modified vaccinia virus Ankara (MVA) into the parental vaccinia virus is not sufficient to reproduce an MVA-like phenotype in cell culture and in mice.
Meisinger-Henschel C, Späth M, Lukassen S, Wolferstätter M, Kachelriess H, Baur K, Dirmeier U, Wagner M, Chaplin P, Suter M, Hausmann J., J Virol 84(19), 2010
PMID: 20668072
Interaction of orthopoxviruses with the cellular ubiquitin-ligase system.
Shchelkunov SN., Virus Genes 41(3), 2010
PMID: 20703935
Genome comparison of a nonpathogenic myxoma virus field strain with its ancestor, the virulent Lausanne strain.
Morales M, Ramírez MA, Cano MJ, Párraga M, Castilla J, Pérez-Ordoyo LI, Torres JM, Bárcena J., J Virol 83(5), 2009
PMID: 19091868
Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity.
Gudmundsdotter L, Nilsson C, Brave A, Hejdeman B, Earl P, Moss B, Robb M, Cox J, Michael N, Marovich M, Biberfeld G, Sandström E, Wahren B., Vaccine 27(33), 2009
PMID: 19450644
Modified vaccinia Ankara strains with identical coding sequences actually represent complex mixtures of viruses that determine the biological properties of each strain.
Suter M, Meisinger-Henschel C, Tzatzaris M, Hülsemann V, Lukassen S, Wulff NH, Hausmann J, Howley P, Chaplin P., Vaccine 27(52), 2009
PMID: 19539582
Evaluation of the efficacy of modified vaccinia Ankara (MVA)/IMVAMUNE against aerosolized rabbitpox virus in a rabbit model.
Garza NL, Hatkin JM, Livingston V, Nichols DK, Chaplin PJ, Volkmann A, Fisher D, Nalca A., Vaccine 27(40), 2009
PMID: 19632316
Survival of lethal poxvirus infection in mice depends on TLR9, and therapeutic vaccination provides protection.
Samuelsson C, Hausmann J, Lauterbach H, Schmidt M, Akira S, Wagner H, Chaplin P, Suter M, O'Keeffe M, Hochrein H., J Clin Invest 118(5), 2008
PMID: 18398511

References

Daten bereitgestellt von Europe PubMed Central.

Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®
Quellen

PMID: 18024893
PubMed | Europe PMC

Suchen in

Google Scholar